SAB Biotherapeutics (NASDAQ:SABS) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note published on Thursday, MarketBeat Ratings reports. The firm issued a buy rating and a $13.00 price objective on the stock.

SABS has been the subject of a number of other research reports. Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Chardan Capital upped their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. UBS Group started coverage on shares of SAB Biotherapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $7.00 price target for the company. Finally, Guggenheim initiated coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They set a “buy” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, SAB Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

SAB Biotherapeutics Stock Up 0.3%

SABS stock opened at $3.88 on Thursday. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The business’s 50 day moving average price is $4.01 and its two-hundred day moving average price is $3.53. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46. The company has a market capitalization of $197.69 million, a price-to-earnings ratio of -1.67 and a beta of 0.60.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). As a group, analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors have recently modified their holdings of the stock. State of Wyoming purchased a new position in shares of SAB Biotherapeutics in the 4th quarter worth about $34,000. ADAR1 Capital Management LLC grew its position in SAB Biotherapeutics by 75.6% during the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after purchasing an additional 11,344 shares during the last quarter. State Street Corp purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at about $49,000. Fifth Lane Capital LP bought a new stake in SAB Biotherapeutics during the 4th quarter valued at about $56,000. Finally, Dimensional Fund Advisors LP purchased a new position in SAB Biotherapeutics in the third quarter worth about $32,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.